1 Characteristics and outcomes of patients treated with sotrovimab

2 to prevent progression to severe COVID-19 in Belgium

- 3 Myriam Drysdale^{1†*}, Thor Hautekiet^{2†}, Moushmi Singh¹, Joris Hautekiet^{3‡}, Linda
- 4 Ludikhuyze³, Vishal Patel^{1‡}, Daniel C Gibbons¹, Dorothée De Roeck⁴, Kirsten Colpaert⁵,
- 5 Emily J Lloyd¹, Eva Van Braeckel^{2,6}
- ¹GSK, Brentford, UK
- 7 ²Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
- 8 ³IQVIA Belux, Zaventem, Belgium
- 9 ⁴GSK, Wavre, Belgium
- ⁵Department of Intensive Care, Ghent University Hospital, Ghent, Belgium
- ⁶Respiratory Infection and Defense Lab, Department of Internal Medicine and Pediatrics,
- 12 Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
- 13
- 14
- ¹⁵ [†]Myriam Drysdale and Thor Hautekiet contributed equally to the manuscript.
- ¹⁶ [‡]Affiliation correct at time of study.
- 17

18 Correspondence:

- 19 *Myriam Drysdale
- 20 myriam.g.drysdale@gsk.com
- 21

22 ORCID IDs:

- 23 Myriam Drysdale: 0000-0002-8994-2816
- 24 Daniel C Gibbons: 0000-0002-3769-9535
- 25 Eva Van Braeckel: 0000-0002-7242-0747

26

27 Abstract

- 28 Background Sotrovimab, a dual-action, engineered human monoclonal antibody, has been
- 29 demonstrated to significantly reduce the risk of hospitalization and death in high-risk patients
- 30 with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab

It is made available under a CC-BY 4.0 International license .

31 treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at

32 high risk of developing severe disease.

Methods This was a multicentric, single-arm observational cohort study of non-hospitalized patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August 2022. We performed a retrospective analysis of hospital, pharmacy and administrative data from nine hospitals in Belgium. The primary outcomes were all-cause and COVID-19-related hospitalizations and all-cause deaths during the 29-day acute follow-up period from first administration of sotrovimab.

39 **Results** A total of 634 patients were included in the analysis (63.4% aged <65 years; 50.3% 40 male). A high proportion (67.7%; n = 429/634) of patients were immunocompromised, with 41 36.9% (*n* = 234/634) actively treated for malignancy. During the 29-day acute period, 12.5% 42 (n = 79/634) of sotrovimab-treated patients were hospitalized due to any cause (median 43 duration 4 days; median time to hospitalization 14 days) and 1.1% (n = 7/634) died due to 44 any cause. In total, 0.8% (n = 5/634) of patients were admitted to an intensive care unit 45 (ICU). COVID-19-related hospitalization was experienced by 2.5% (n = 16/634) of patients 46 (median duration 10 days; median time to hospitalization 10.5 days), with 0.5% (n = 3/634) 47 of patients admitted to an ICU. COVID-19-related hospitalization was experienced by 6.3% 48 (n = 3/48) of patients during Delta predominance (04/11/2021-23/12/2021), 6.3% (n = 1/16)49 of patients during Delta/BA.1 codominance (24/12/2021-01/01/2022), 1.4% (n = 3/218) of 50 patients during BA.1 predominance (02/01/2022-09/02/2022), 2.1% (n = 2/97) of patients 51 during BA.1/BA.2 codominance (10/02/2022-07/03/2022) and 2.7% (*n* = 7/255) of patients 52 during BA.2/BA.5 codominance (08/03/2022–02/08/2022).

53 Conclusions This observational study demonstrated consistently low rates of COVID-19-

related hospitalizations and all-cause deaths in sotrovimab-treated patients during the

55 Omicron subvariant periods in Belgium, despite over two-thirds of the study population being

It is made available under a CC-BY 4.0 International license .

56 immunocompromised. Comparative effectiveness studies are warranted to confirm

57 sotrovimab effectiveness in highly immunocompromised patients with COVID-19.

58 Keywords: COVID-19; monoclonal antibody; Omicron BA.1; Omicron BA.2; SARS-CoV-2;

59 sotrovimab

60 Background

61 Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory

62 syndrome coronavirus 2 (SARS-CoV-2); the rapid global spread of SARS-CoV-2 resulted in

63 the declaration of a pandemic by the World Health Organization in March 2020 [1]. Globally,

as of September 2023, there have been over 770 million confirmed cases of COVID-19,

65 including nearly 7 million deaths [2]. In Belgium, almost 158,000 hospitalizations and 34,000

66 deaths have been attributed to COVID-19 during the same period [2, 3].

Older individuals or those with immunosuppression, cancer, obesity, diabetes, or
chronic kidney, lung, liver or cardiovascular disease are known to be at higher risk of
developing severe COVID-19, which may result in hospitalization or death [4-6].

Sotrovimab is a dual-action, engineered human immunoglobulin G1κ monoclonal
antibody (mAb) derived from the parental mAb S309, a potent neutralising mAb directed
against the spike protein of SARS-CoV-2 [7-10]. Sotrovimab (administered as a single
500 mg intravenous dose) was shown in COMET-ICE, a randomized clinical trial, to
significantly reduce the risk of all-cause >24-hour hospitalization or death compared with
placebo in high-risk patients with COVID-19 [11].

As a result of positive findings from COMET-ICE, sotrovimab received marketing
authorization from the European Medicines Agency (EMA) in December 2021 for use in
adults and adolescents (aged ≥12 years and weighing ≥40 kg) with COVID-19 who do not
require oxygen supplementation and are at increased risk of progressing to severe

It is made available under a CC-BY 4.0 International license .

80	COVID-19 [12]. In Belgium, use of sotrovimab began prior to EMA approval as a result of a
81	procurement framework contract issued by the European Commission in July 2021 that
82	enabled participating European Union member states, including Belgium, to purchase
83	sotrovimab prior to its marketing authorization [13, 14]. At the time of the study, mAbs
84	(including sotrovimab) were recommended for the treatment of mild-to-moderate COVID-19
85	among patients in Belgium at high risk of complications, following authorization by a
86	multidisciplinary team including at least one infectious disease physician and one
87	immunologist [15]. Due to limited supplies of mAbs, immunocompromised patients were
88	considered the highest priority for mAb treatment [15].
89	Sotrovimab has been granted marketing authorization in the European Union,
90	Norway, Iceland [16], Australia (conditional) [17], United Kingdom (conditional) [18], Saudi
91	Arabia (conditional) [19] and Switzerland (conditional) [19]. In Japan, a Special Approval for
92	Emergency designation has been granted [20]. Since the approval of sotrovimab, waves of
93	new SARS-CoV-2 variants of concern have emerged, including the Delta variant and the
94	Omicron BA.1, BA.2 and BA.5 subvariants; the latter became dominant in Belgium in June
95	2022 [21-23]. In vitro neutralization studies have demonstrated a moderate fold shift in
96	activity of sotrovimab against Omicron BA.2 relative to wild-type SARS-CoV-2 (16-fold
97	change in EC_{50} relative to wild-type) [24]. A similar reduction in activity was reported for
98	sotrovimab against BA.5 (22.6-fold change in EC_{50} relative to wild-type) [24]. Consequently,
99	on 28 April 2022, the Federal Agency for Medicines and Health Products regulatory body in
100	Belgium took the decision to no longer recommend the use of sotrovimab [25], although use
101	continued among very-high-risk and/or immunocompromised patients.
102	In the absence of a clinical trial conducted during the Omicron predominance period,

102 In the absence of a clinical trial conducted during the Omicron predominance period, 103 it remains uncertain how *in vitro* antibody neutralization activity correlates with clinical 104 effectiveness, especially for dual-action antibodies like sotrovimab that have potent effector 105 function, including antibody-dependent cellular cytotoxicity and antibody-dependent cellular 106 phagocytosis [10, 26, 27]. Real-world studies are an important source of data with which to

It is made available under a CC-BY 4.0 International license .

107 assess clinical outcomes in patients treated with sotrovimab within the evolving variant

108 landscape.

Here, we describe the real-world use of, and outcomes from, sotrovimab treatment for the management of patients with COVID-19 at high-risk of developing severe disease between 1 November 2021 and 2 August 2022 in Belgium, when the Delta variant and Omicron BA.1, BA.2 and BA.5 subvariants were predominant.

113 Methods

114 Study design and data source

115 In this single-arm observational cohort study, data were collected retrospectively from nine 116 centres (including two university hospitals) located in Flanders, Brussels and Wallonia that 117 administered sotrovimab in an outpatient setting from 1 November 2021 up to and including 118 2 August 2022. Patient-level data were collected and aggregated from three main sources: 119 1) registered administrative, medical and nursing data, which are fully structured and 120 standardized across all hospitals and therefore require no specific technology to be 121 implemented for data retrieval; 2) structured and standardized hospital pharmacy or 122 invoicing data using predefined Anatomical Therapeutic Chemical (ATC) codes to capture 123 the date of sotrovimab administration; 3) administrative data regarding hospital admission 124 and transfer.

The index date (Day 1) was defined as the date of first treatment administration with sotrovimab. The baseline period was defined as the 1 year prior to index for assessment of prior comorbidities. All-cause and COVID-19-related outcomes were reported during the acute period, defined as the 29-day follow-up period starting on the index date. End of follow-up was defined as either the end of the acute period, death or the study end (31 August 2022), whichever occurred first.

It is made available under a CC-BY 4.0 International license .

This study complies with all applicable laws regarding subject privacy. No direct subject contact or primary collection of individual human subject data occurred. Study results were in tabular form and were aggregate analyses that omitted subject identification; therefore, informed consent was not required. Ethics committee approval was obtained from each of the participating centres, with the exception of AZ Maria Middelares, AZ Groeninge

and Jan Yperman where approval was provided by a data access committee.

137 Study population

138 Non-hospitalized patients infected with SARS-CoV-2 were eligible for inclusion if they were

139 aged ≥12 years on the index date and received outpatient treatment with sotrovimab for the

140 first time during the study period.

Patients were excluded if they received sotrovimab in an inpatient setting and/or received remdesivir as an early treatment in an outpatient setting during the acute period. However, in three of the study centres, patients routinely stayed in hospital overnight after sotrovimab administration for logistical (i.e. for monitoring post treatment administration) rather than medical reasons; therefore, the exclusion criteria were adapted for these centres to include patients discharged the day after sotrovimab administration.

147 Study outcomes

148 Patient demographics and clinical characteristics were collected based on the presence of

149 selected International Classification of Disease version 10 (ICD-10) and ATC codes (Tables

150 S1–S3) during any hospital visit that occurred in the 12 months prior to the index date.

151 These included age, sex, and comorbidities and risk factors that may predispose patients to

152 severe COVID-19 outcomes, as follows: immunocompromised status (human

153 immunodeficiency virus infection/acquired immunodeficiency syndrome, treatment for solid

tumours, haematological malignancy, solid organ or haematopoietic stem cell

155 transplantation, primary immune deficiency, receiving immunosuppressive drugs [see Table

156 **S1**], sickle-cell anaemia, major thalassaemia, asplenia); other risk factors or comorbidities of

It is made available under a CC-BY 4.0 International license .

157 interest (age \geq 65 years old, obesity, type 1 or type 2 diabetes mellitus, chronic lung disease 158 including asthma and cystic fibrosis, cardiovascular disease including uncontrolled 159 hypertension, chronic kidney disease [CKD; estimated glomerular filtration rate <30 ml/min] 160 including treatment via haemodialysis, chronic liver disease [Child-Pugh B or C], chronic 161 neurological disease). These comorbidities and risk factors for severe COVID-19 aligned 162 with those reported by the Scientific Institute for Public Health of the Federal Belgian State 163 (Sciensano) and the US Centers for Disease Control and Prevention [5, 6]. 164 The clinical outcomes of this study included the number and proportion of all-cause

and COVID-19-related hospitalizations and all-cause deaths during the acute period (29 days after the index date). COVID-19-related hospitalizations were defined as having the following ICD-10 codes registered as the verified admission diagnosis: B34.2, B97.2 or U07.1 (**Table S2**). In a *post hoc* analysis, cause of death data were collected for patients at Ghent University Hospital and the proportion of COVID-19-related deaths was determined; only all-cause deaths are reported for the other centres.

171 The number and proportion of all-cause and COVID-19-related hospitalizations and 172 all-cause deaths among sotrovimab-treated patients were reported for the overall population 173 and stratified by week and month, as well by the period of SARS-CoV-2 variant 174 predominance in Belgium [28], as follows: Delta predominance period, 4 November 2021-175 23 December 2021; Delta/BA.1 codominance period, 24 December 2021–1 January 2022; 176 BA.1 predominance period, 2 January 2022–9 February 2022; BA.1/BA.2 codominance 177 period, 10 February 2022–7 March 2022; BA.2/BA.5 codominance period, 8 March 2022–2 178 August 2022 (Fig. 1). The study design did not enable collection of polymerase chain 179 reaction results in order to identify the SARS-CoV-2 variant strains that patients were 180 infected with. Rather, to map the 29-day outcomes with the circulating variants, we used a 181 proxy based on the most prevalent strains circulating in Belgium per week, as provided by 182 Sciensano [28].

It is made available under a CC-BY 4.0 International license .

In addition, the length of stay (defined as number of hospitalization days), time to
hospitalization after the index date, number and proportion of patients admitted to intensive
care, and the number and proportion of patients receiving non-invasive or mechanical
ventilation during all-cause or COVID-19-related hospitalization were captured during the
acute period.

In an exploratory analysis, all-cause and COVID-19-related new hospitalizations and
all-cause deaths reported during the post-acute period, defined as the period between Day
30 and Day 90 after the index date, were assessed. Data for the exploratory analysis could
only be collected for patients identified on or before 1 June 2022 to allow time for Day 30–90
follow-up to be completed before the end of the study period (31 August 2022).

193 Data analysis

Descriptive analyses were performed. For continuous variables, the mean, standard deviation (SD), median and interquartile range (IQR) were calculated. Proportions were calculated using the total number of eligible patients treated with sotrovimab as the denominator, unless otherwise specified. The prevalence of hospitalization or death during the respective SARS-CoV-2 variant predominance periods was calculated as the number of patients who experienced that event during the variant predominance period divided by the total number of sotrovimab-treated patients during that period multiplied by 100.

For post-acute 90-day outcomes, the proportions of hospitalizations (all-cause and COVID-19-related) and deaths (all-cause) were calculated among the number of patients treated with sotrovimab who were still alive at the beginning of the post-acute period and had completed the 90-day follow-up.

It is made available under a CC-BY 4.0 International license .

205 **Results**

206 Patient identification and characteristics

- 207 Following application of the inclusion and exclusion criteria, 634 patients were included in
- the study (**Table 1**). A total of 598 patients identified across the study centres had received
- sotrovimab while already hospitalized and were excluded from the study. No patients
- 210 identified had received remdesivir as an outpatient during the acute COVID-19 infection
- 211 period.
- 212 **Table 1** Number of patients excluded and included per study centre (1 November 2021–2
- 213 August 2022)

		Non-e			
Study centre	Number of patients identified as treated with sotrovimab	Number of patients treated with sotrovimab in a hospitalized setting*	Number of patients treated with remdesivir during the acute COVID-19 infection period	Number of patients eligible for inclusion in study analysis	
UZ Gent	650	272	0	378	
Hôpital Erasme	119	70	0	49	
AZ Damiaan	26	26 22		4	
AZ Groeninge	58	27	0	31	
AZ Jan Yperman	73	28	0	45	
AZ Sint- Lucas	48	31	0	17	
AZ Maria Middelares	149	78	0	71	
CHU Ambroise Paré	35	13	0	22	
CHU					
Clinique Saint-Pierre	74	57	0	17	
Total	1232	598	0	<i>N</i> = 634	

It is made available under a CC-BY 4.0 International license .

215	*At AZ Sint-Lucas, CHU Clinique Saint-Pierre and CHU Ambroise Paré, patients routinely stayed in hospital
216	overnight after sotrovimab administration for logistical (i.e. for monitoring post treatment administration) rather
217	than medical reasons; therefore, the exclusion criteria were adapted for these centres to include patients
218	discharged the day after sotrovimab administration
219	Table 2 presents the baseline demographic and clinical characteristics among
220	sotrovimab-treated patients included in the analysis. The patients were predominantly aged
221	<65 years (63.4%, <i>n</i> = 402/634), with more than one-third (38.6%, <i>n</i> = 245/634) of patients
222	aged 18–54 years. Half of the patients (50.3%, $n = 319/634$) were male, and 67.7% ($n =$
223	429/634) were immunocompromised and thus considered at high risk of developing COVID-
224	19 complications. Most of the immunocompromised patients had a malignancy and were
225	undergoing treatment with antineoplastic agents, endocrine therapies or immunostimulants
226	(36.9%, $n = 234/634$), or had primary immune deficiency (29.7%, $n = 188/634$) or a
227	haematological malignancy (25.4%, $n = 161/634$). With respect to the other risk factors and
228	comorbidities of interest (excluding age \geq 65 years), cardiovascular disease (17.7%, <i>n</i> =
229	112/634), diabetes (12.3%, $n = 78/634$) and CKD (10.6%, $n = 67/634$) were the most
230	common.

Characteristic	Sotrovimab			
	(<i>N</i> = 634)			
Age group, years, <i>n</i> (%)				
12–17	23 (3.6)			
18–54	245 (38.6)			
55–64	134 (21.1)			
65–74	140 (22.1)			
≥75	92 (14.5)			
Male sex, <i>n</i> (%)	319 (50.3)			
Immunocompromised patients at high risk of				
developing COVID-19 complications, <i>n</i> (%)				
≥1 high-risk criterion	429 (67.7)			
HIV/AIDS	4 (0.6)			
Solid tumour	85 (13.4)			
Cancer undergoing treatment: radiotherapy	0			
Cancer undergoing treatment: radio- or	9 (1 2)			
chemotherapy	8 (1.3)			

231 Table 2 Patient characteristics

It is made available under a CC-BY 4.0 International license .

Cancer undergoing treatment: drugs	234 (36.9)
Haematological malignancy	161 (25.4)
Solid organ or haematopoietic stell cell transplantation	121 (19.1)
Primary immune deficiency	188 (29.7)
Immunosuppressive drugs	120 (18.9)
Sickle cell anaemia	3 (0.5)
Major thalassaemia	0
Asplenia	0
Other risk factors/comorbidities of interest, n (%)	
≥1 other comorbidity of interest	364 (57.4)
Age ≥65 years	232 (36.6)
Obesity with BMI ≥30 kg/m ²	42 (6.6)
Type 1 or type 2 diabetes mellitus	78 (12.3)
Chronic lung disease, including asthma	36 (5.7)
Cardiovascular disease, including uncontrolled hypertension	112 (17.7)
Chronic kidney disease (eGFR <30 ml/min), including haemodialysis	67 (10.6)
Chronic liver disease (Child–Pugh B or C)	30 (4.7)
Chronic neurological disease	23 (3.6)

AIDS=acquired immunodeficiency syndrome; BMI=body mass index; COVID-19=coronavirus disease 2019;

233 eGFR=estimated glomerular filtration rate; HIV=human immunodeficiency virus

234 Overall analysis of acute period (29-day) clinical outcomes

235 All-cause clinical outcomes

- Among the 634 sotrovimab-treated patients, 82 (12.9%) were hospitalized or died due to any
- cause within the 29-day acute period (**Table 3**). Seventy-nine (12.5%) patients were
- hospitalized for any cause and seven (1.1%) died due to any cause during the 29-day acute
- period. Of the 79 patients who had all-cause hospitalization events, 12 (15.2%) had more
- than one hospitalization event during the acute phase. Among hospitalized patients, the
- 241 median (IQR) duration of the first all-cause hospitalization was 4.0 (2.0, 9.0) days. Median
- 242 (IQR) time to first all-cause hospitalization from the index date was 14.0 (9.5, 22.0) days.
- Five (6.3%) of the patients with all-cause hospitalizations were admitted to the intensive care
- unit (ICU), with a median (IQR) stay of 6.0 (4.0, 9.0) ICU days. Two patients required
- 245 mechanical ventilation and one patient required non-invasive ventilation.

246 COVID-19-related clinical outcomes

It is made available under a CC-BY 4.0 International license .

247	COVID-19-related hospitalizations during the 29-day acute period were experienced by 2.5%
-----	---

(n = 16/634) of patients (**Table 3**). The median (IQR) duration of stay was 10.0 (6.8, 14.2)

- 249 days. Median (IQR) time to hospitalization from the index date was 10.5 (2.2, 20.8) days. Of
- 250 patients with COVID-19-related hospitalizations, three (18.8%) were admitted to an ICU, with
- a median (IQR) stay of 4.0 (4.0, 6.5) ICU days. One patient required mechanical ventilation.
- 252 Of the 378 patients treated with sotrovimab at Ghent University Hospital, four (1.1%)
- died due to any cause, including one patient who died as a result of COVID-19
- 254 complications.
- 255 Table 3 Acute period (29-day) all-cause and COVID-19-related outcomes

Outcome	Patients treated with sotrovimab (<i>N</i> = 634)
All-cause hospitalization or death, <i>n</i> (%)	82 (12.9)
All-cause hospitalization, n (%)	79 (12.5)
All-cause hospitalization events, <i>n</i> (%)	
0	555 (87.5)
1	67 (10.6)
2	10 (1.6)
3	2 (0.3)
All-cause deaths, <i>n</i> (%)	7 (1.1)
Number of all-cause hospitalization days	
Mean (SD)	8.3 (12.5)
Median (IQR)	4.0 (7.0)
Time to hospitalization from index date in days	
Mean (SD)	14.9 (7.8)
Median (IQR)	14.0 (12.5)
	14.0 (12.3)
All-cause ICU admission, <i>n</i> (%)	5 (0.8)
Number of ICU days	
Mean (SD)	7.2 (3.8)
Median (IQR)	6.0 (5.0)
All-cause non-invasive ventilation, n (%)	1 (0.2)
All-cause mechanical ventilation, n (%)	2 (0.3)
COVID-19-related hospitalization, <i>n</i> (%)	16 (2.5)*
Number of COVID-19-related hospitalization days	
Mean (SD)	14.0 (16.3)
Median (IQR)	10.0 (7.5)
	10.0 (7.3)
Time to COVID-19-related hospitalization from index	
date in days	11.4 (8.9)

It is made available under a CC-BY 4.0 International license .

Mean (SD) Median (IQR)	10.5 (18.5)
COVID-19-related ICU admission, n (%)	3 (0.5)
Number of COVID-19-related ICU days Mean (SD) Median (IQR)	5.7 (2.9) 4.0 (2.5)
COVID-19-related non-invasive ventilation, n (%)	0
COVID-19-related mechanical ventilation, n (%)	1 (0.2)

256

257 *Fifteen patients (2.4%) had a first COVID-19-related hospitalization during the 29-day acute period. One patient

258 was hospitalized for the first time during the 29-day acute period for reasons unrelated to COVID-19, but a

subsequent hospitalization during the same period was COVID-related. COVID-19=coronavirus disease 2019,

260 ICU=intensive care unit, IQR=interquartile range, SD=standard deviation

Acute period (29-day) clinical outcomes during periods of Delta and Omicron

262 predominance

- 263 The 29-day acute period all-cause and COVID-19-related outcomes by period of SARS-
- 264 CoV-2 variant predominance are shown in Table 4. The largest number of sotrovimab-
- treated patients were observed during the BA.1 (34.4%, n = 218/634) and BA.2/BA.5
- 266 codominance (40.2%, *n* = 255/634) periods.
- 267 During the Delta predominance period, the proportion of sotrovimab-treated patients
- hospitalized due to any cause was 22.9% (n = 11/48). During the Delta/BA.1 codominance,
- 269 BA.1 predominance, BA.1/BA.2 codominance and BA.2/BA.5 codominance periods, all-
- 270 cause hospitalizations were experienced by 18.8% (*n* = 3/16), 11.5% (*n* = 25/218), 8.2% (*n* =
- 271 8/97) and 12.5% (*n* = 32/255) of patients, respectively.
- 272 COVID-19-related hospitalizations were experienced by 6.3% (n = 3/48) of
- sotrovimab-treated patients during the period of Delta predominance, 6.3% (n = 1/16) in the
- Delta/BA.1 codominance period, 1.4% (n = 3/218) in the BA.1 predominance period, 2.1% (n
- 275 = 2/97) in the BA.1/BA.2 codominance period and 2.7% (n = 7/255) in the BA.2/BA.5
- codominance period (**Table 4**).

It is made available under a CC-BY 4.0 International license .

- 277 No sotrovimab-treated patients died during the Delta predominance period (**Table 4**).
- 278 During the Delta/BA.1 codominance period, one sotrovimab-treated patient died (n = 1/16).
- Two patients died in each of the BA.1 predominance (n = 2/218), BA.1/BA.2 codominance (n
- 280 = 2/97) and BA.2/BA.5 codominance (n = 2/255) periods.
- Table 4 Acute period (29-day) all-cause and COVID-19-related outcomes by period of
- 282 SARS-CoV-2 variant predominance

Outcome	Overall	Delta predominance 04/11/2021– 23/12/2021	Delta/BA.1 codominance 24/12/2021– 01/01/2022	BA.1 predominance 02/01/2022– 09/02/2022	BA.1/BA.2 codominance 10/02/2022– 07/03/2022	BA.2/BA.5 codominance* 08/03/2022– 02/08/2022
Number of patients treated with sotrovimab	634	48	16	218	97	255
Hospitalized due to any cause, <i>n</i> (%)	79 (12.5)	11 (22.9)	3 (18.8)	25 (11.5)	8 (8.2)	32 (12.5)
Hospitalized due to COVID-19, <i>n</i> (%)	16 (2.5)	3 (6.3)	1 (6.3)	3 (1.4)	2 (2.1)	7 (2.7)
Hospitalized due to unknown reason, <i>n</i> (%)	7 (1.1)	0 (0.0)	1 (6.3)	6 (2.8)	0 (0.0)	0 (0.0)
Died due to any cause, <i>n</i> (%)	7 (1.1)	0 (0.0)	1 (6.3)	2 (0.9)	2 (2.1)	2 (0.8)

283 284

*BA.5 took over from BA.2 as the dominant strain on 25 June 2022. COVID-19=coronavirus disease 2019,

285 SARS-CoV-2=severe acute respiratory syndrome coronavirus 2

286 Exploratory analysis of post-acute period (30–90-day) clinical outcomes

- 287 In total, 625 patients had follow-up data available for the post-acute period, defined as 30-
- 288 90 days after the first sotrovimab administration (index date). Among these patients, 13.8%
- (n = 86/625) had a new hospitalization event (any cause), 1.6% (n = 10/625) had a COVID-

It is made available under a CC-BY 4.0 International license .

290 19-related hospitalization and 1.1% (n = 7/625) died due to any cause during the post-acute 291 period.

At Ghent University Hospital, 30–90-day follow-up data were available for 374 patients. Among these patients, five died (1.3%), with two deaths due to COVID-19-related reasons.

295 **Discussion**

296 This single-arm, retrospective study describes the real-world clinical outcomes of patients 297 with COVID-19 who received sotrovimab treatment across nine hospitals in Belgium 298 between 1 November 2021 and 31 August 2022. Over two-thirds (67.7%) of the patients in 299 this study had at least one immunocompromising condition, with over one-third of patients 300 (36.9%) receiving chemotherapy for an underlying malignancy. Other commonly reported 301 risk factors for progression to severe COVID-19 were age ≥ 65 years old, cardiovascular 302 diseases (including uncontrolled hypertension), diabetes and CKD. Comparatively, national 303 hospital surveillance, conducted by Sciensano, identified hypertension, cardiovascular 304 disease and diabetes as the top three most frequently reported comorbidities among 305 patients with COVID-19 hospitalized in Belgium over the course of the pandemic [29].

306 During this study, 12.9% of patients (n = 82/634) treated with sotrovimab were 307 hospitalized or died due to any cause during the 29-day acute period. This rate is relatively 308 high compared with rates reported in other retrospective or observational studies (all-cause 309 hospitalization and/or mortality ranged from 2.1% to 2.7% during the BA.1 predominance 310 period and from 1.7% to 2.0% during the BA.2 predominance period in a recent systematic 311 literature review reporting on the real-world effectiveness of sotrovimab [30]), but this may be 312 potentially explained by several observations. Firstly, high proportions of all-cause and 313 COVID-19-related hospitalizations were mainly observed among sotrovimab-treated patients 314 during the Delta predominance period (4 November to 23 December 2021) in Belgium.

It is made available under a CC-BY 4.0 International license .

315 These observations align with nationally reported records of high rates of COVID-19-related 316 hospitalization (12,588 admissions) and deaths (1935) during the Delta predominance period 317 [3, 31] and may reflect the higher disease severity, higher prevalence and more rigorous 318 public health measures associated with the Delta variant relative to subsequent Omicron 319 variants, as well as lower immunity within the population [32, 33]. Additionally, the present 320 study period spanned four SARS-CoV-2 variants (Delta, BA.1, BA.2 and BA.5) compared 321 with one to two variants (primarily BA.1 or BA.2) in other studies [34-36]. Furthermore, the 322 current study had a relatively high proportion of patients with at least one 323 immunocompromising condition (67.7%) compared with other studies [34, 35, 37, 38]. This 324 higher proportion of high-risk patients, necessitating regular inpatient treatment for their 325 underlying conditions, may explain the relatively higher rate of all-cause hospitalization or 326 mortality observed in this current study compared with other real-world studies [30, 34, 35, 327 39].

328 In a recent Danish cohort study, 83% of 2933 sotrovimab-treated patients belonged 329 to very-high-risk groups that included haematological malignancy, solid organ 330 transplantation, and treatment with anti-CD20 for non-malignant haematological diseases 331 within the previous year. Within 90 days of sotrovimab treatment (696 person-years), 30.2% 332 of patients were hospitalized and 5.3% had died due to any cause. The highest prognostic 333 factor was haematological malignancy, followed by age ≥65 years [40]. Comparatively, in our 334 study, 68% of patients had at least one immunocompromising condition. A guarter (25.4%) 335 of patients had a haematological malignancy and 36.6% were aged ≥65 years; our 30–90-336 day results show that 13.8% of patients had a new hospitalization event (any cause), and 337 1.1% died due to any cause. Similar to our findings, the Danish study found a higher 338 proportion of hospitality and death associated with the Delta variant, but no major differences 339 in these outcomes were observed between the Omicron BA.1 and BA.2 variants [40]. 340 In our study population, the proportion of sotrovimab-treated patients experiencing

341 COVID-19-related hospitalization was highest during the Delta predominance and

It is made available under a CC-BY 4.0 International license .

Delta/BA.1 codominance (both 6.3%) periods. During the BA.1 predominance, BA.1/BA.2 codominance and BA.2/BA.5 codominance periods, COVID-19-related hospitalizations were consistently low (all \leq 2.7%). The median duration of hospitalization in our study (10.0 days) was higher than the national reported figure for Belgium, of 2 days, during the Omicron predominance period [41]; however, the median duration of ICU stays (4.0 days) was the same as the national median duration reported for Belgium [41]. It should be noted that the number of patients admitted to an ICU was low (n = 3), which limits interpretation.

349 This study has several potential limitations that should be considered. Firstly, this 350 descriptive, single-arm study did not include a comparator arm, such as patients with similar 351 risk profiles who did not receive sotrovimab after SARS-CoV-2 infection. We were not able to 352 derive a control group due to a lack of similarly high-risk patients who had not received 353 sotrovimab treatment and because patients who did not receive sotrovimab and were not 354 hospitalized were not accounted for in the data used in this study. As a result, it is difficult to 355 infer an association between sotrovimab treatment and clinical outcomes from these data 356 alone. Due to the retrospective, observational study design, variables such as vaccination 357 status and disease severity at enrolment could not be extracted, as these were not 358 structurally reported and standardized in all hospitals. However, vaccination rates in Belgium 359 had reached 73% by the start of this study [42] (and were presumably higher in high-risk 360 groups similar to this study population). Furthermore, one might assume a high vaccination 361 uptake in this population, with patients having received regular follow-up at their treating 362 hospital and being eligible for early treatment with mAbs. Patients who received sotrovimab 363 as an inpatient were excluded from the study, with the exception of patients who were 364 discharged the day after sotrovimab administration. This comprised a large proportion of the 365 total number of patients identified (48.5% [n = 598/1232], potentially inducing selection bias 366 in the analyses and limiting the generalizability of the findings. In addition, patients who 367 received sotrovimab in one of the selected hospitals but were later admitted to a different 368 hospital where they progressed to severe disease may not have been captured in our study

It is made available under a CC-BY 4.0 International license .

369 given its retrospective nature. However, as sotrovimab is expected to be primarily used in 370 patients at risk of progressing to severe outcomes, such as those who are 371 immunocompromised, these patients were likely associated with a reference hospital given 372 their need for frequent medical care; therefore, missing data for clinical outcomes were likely 373 to be low. Similarly, data on the uptake of immunosuppressant drugs and diagnosis of 374 comorbidities were only extractable for patients who were treated or diagnosed in the same 375 hospital where they received their sotrovimab treatment. Information on drugs received in 376 another hospital or prescribed in primary care were not available. Therefore, the number of 377 patients who were at high risk of developing severe COVID-19 disease may have been 378 underestimated. Lastly, as variant sequencing was not routinely undertaken, the specific 379 SARS-CoV-2 variant with which patients were infected could not be determined. Instead, an 380 ecological design was proposed that used the periods of Delta, BA.1, BA.2 and BA.5 381 subvariant predominance and codominance as a proxy for the infecting variant. National 382 genomic surveillance data were used to stratify the study periods into circulating variant 383 predominance periods [28].

384 **Conclusions**

This observational study demonstrated consistently low rates of COVID-19-related hospitalizations and all-cause deaths in sotrovimab-treated patients during the Omicron subvariant predominance periods in Belgium, despite the reported decrease in *in vitro* neutralization activity of sotrovimab against BA.2 and BA.5, and over two-thirds of the study population being immunocompromised. Comparative effectiveness studies are warranted to confirm the effectiveness of sotrovimab in highly immunocompromised patients with COVID-19.

392 List of abbreviations

- 393 ATC Anatomical Therapeutic Chemical
- 394 CKD chronic kidney disease

It is made available under a CC-BY 4.0 International license .

395	COVID-19	coronavirus disease 2019
396	EMA	European Medicines Agency
397	ICD-10	International Classification of Disease version 10
398	ICU	intensive care unit
399	IQR	interquartile range
400	mAb	monoclonal antibody
401	SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
402	SD	standard deviation

403 **Declarations**

404 Acknowledgements

- The authors wish to thank the Ghent University Hospital Data Science Institute for its support
- 406 and role in this study.
- 407 Editorial support (in the form of writing assistance, including preparation of the draft
- 408 manuscript under the direction and guidance of the authors, collating and incorporating
- 409 authors' comments for each draft, assembling tables, grammatical editing and referencing)
- 410 was provided by Kathryn Wardle and Tony Reardon of Apollo, OPEN Health
- 411 Communications, in accordance with Good Publication Practice guidelines
- 412 (<u>www.ismpp.org/gpp-2022</u>). The support was funded by GSK and Vir Biotechnology, Inc.

413 Authors' contributions

414 Conception: MD, VP, DCG, EJL, JH, LL

- 415 Study design: MD, VP, DCG, EJL, JH, LL, TH, KC, EVB
- 416 Execution: MD, VP, DCG, EJL, JH, LL, TH, KC, EVB, MS
- 417 Acquisition of data: TH, KC, EVB
- 418 Analysis and interpretation: MD, VP, DCG, EJL, JH, LL, TH, KC, EVB, MS
- 419 All authors took part in drafting, revising or critically reviewing the manuscript; gave final
- 420 approval of the version to be published; have agreed on the journal to which the article has
- 421 been submitted; and agree to be accountable for all aspects of the work.

422 Funding

423 This study was funded by GSK and Vir Biotechnology, Inc. (study number 214878).

424 Availability of data and materials

The datasets used and/or analysed during the current study are not available due to dataprivacy.

427 Competing interests

MS, VP (at time of study), DCG, MD, DDR and EJL are employees of, and/or shareholders in, GSK. JH (at time of study) and LL are employees of IQVIA, which received funding from GSK and Vir Biotechnology, Inc. to conduct the study. TH, KC and EVB are employees of Ghent University Hospital, which received funding from GSK and Vir Biotechnology, Inc. to conduct the study. EVB also declares speaker fees paid to her institution from GSK, Gilead and Pfizer.

It is made available under a CC-BY 4.0 International license .

434 Ethics approval and consent to participate

435	This study complies with all applicable laws regarding subject privacy. No direct subject
436	contact or primary collection of individual human subject data occurred. Study results were in
437	tabular form and were aggregate analyses that omit subject identification; therefore,
438	informed consent was not required. Ethics committee approval was obtained from each of
439	the participating centres (CHU Saint-Pierre - Comité local d'éthique hospitalier [n° 007]; CHU
440	Ambroise Paré - Comité d'éthique hospitalier; AZ Damiaan - Ethisch comité [n° 057]; AZ Sint
441	Lucas Gent - Commissie medische ethiek; Hôpital Erasme ULB - Comité d'éthique
442	hospitalo-facultaire; UZ Gent - Commissie voor medische ethiek), with the exception of AZ
443	Maria Middelares, AZ Groeninge and Jan Yperman. For AZ Maria Middelares, formal ethics
444	committee approval is not required for retrospective database studies; however, the study
445	was approved by a data protection board that oversees information security, ethical and
446	financial aspects in the context of secondary reuse of health data. For AZ Groeninge and
447	Jan Yperman, formal ethics approval is not required for retrospective studies; however, a
448	data access committee at each centre (with medical legal and ethics committee
449	representation) approved the study.

450 **Consent for publication**

451 Not applicable.

It is made available under a CC-BY 4.0 International license .

452 **References**

- 453 1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed.
- 454 2020;91:157-60.
- 455 2. World Health Organization. WHO coronavirus (COVID-19) dashboard.
- 456 https://covid19.who.int/. Accessed 21 September 2023.
- 457 3. Sciensano. Belgium COVID-19 epidemiological situation: hospitalisations.
- 458 https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-
- 459 0369173148ab/page/uTSKB. Accessed 21 September 2023.
- 460 4. Hoge Gezondheidsraad. Aanbevelingen voor het prioriteren van subgroepen van
- 461 patiënten jonger dan 65 jaar voor vaccinatie tegen SARS-CoV-2 (fase lb). HGR NR.
- 462 9618 [Recommendations for prioritizing subgroups of patients younger than 65 years
- 463 for vaccination against SARS-COV-2 (phase IB). HGR NR. 9618].
- 464 https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/2
- 465 0210205_hgr-9618_priorites_vaccination_covid-19_vweb.pdf. Accessed 21
- 466 September 2023.
- 467 5. Centers for Disease Control and Prevention. Underlying medical conditions
- 468 associated with higher risk for severe COVID-19: information for healthcare
- 469 professionals. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-
- 470 care/underlyingconditions.html. Accessed 21 September 2023.
- 471 6. Sciensano. Belgium COVID-19 epidemiological situation: summary.
- 472 https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-
- 473 0369173148ab/page/ZwmOB. Accessed 21 September 2023.
- 474 7. Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, et
- 475 al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal

It is made available under a CC-BY 4.0 International license .

476	antibody	VRC01LS: a	ohase 1 o	pen-label	clinical trial in	health	/ adults.	PLoS Med
4/0	antibuuy	VINCUILO. a	pliase i u	pen-iaper	ciinicai thai in	nealun	auuits.	FLUS Med

477 2018;15:e1002493.

- 478 8. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal
- 479 Fc receptor function improves protection against primate SHIV infection. Nature.
 480 2014;514:642-5.
- 9. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Crossneutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature.
 2020;583:290-5.
- 484 10. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al.
- 485 The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent
- 486 in vitro and in vivo activity against SARS-CoV-2. bioRxiv.
- 487 2021;doi.org/10.1101/2021.03.09.434607.
- 488 11. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D,
- 489 et al. Effect of sotrovimab on hospitalization or death among high-risk patients with
- 490 mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327:1236-46.
- 491 12. European Medicines Agency. Xevudy summary of product characteristics
- 492 https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product493 information_en.pdf. Accessed 21 September 2023.
- 494 13. European Commission. Daily News 28 / 07 / 2021. Coronavirus: commission signs
 495 contract to procure monoclonal anti-body treatment.
- 496 https://ec.europa.eu/commission/presscorner/detail/en/mex_21_3942. Accessed 21
 497 September 2023.
- 498 14. Arickx F, Blot K, Bottieau E, Callens S, Daems J, Dauby N, et al. Task Force COVID
 499 Therapeutics. Advice regarding the purchase of sotrovimab (Xevudy) for the

It is made available under a CC-BY 4.0 International license .

- 500 treatment of COVID-19 patients in Belgium.
- 501 https://kce.fgov.be/sites/default/files/2022-
- 502 02/Task_Force_COVID_Therapeutics_20210202_Advice_on_the_purchase_of__sotr
- 503 ovimab.pdf. Accessed 21 September 2023.
- 504 15. Sciensano. Interim clinical guidance for adults with suspected or confirmed COVID-

505 19 in Belgium; version 26. Accessed 21 September 2023.

- 506 16. European Medicines Agency. Xevudy.
- 507 https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy. Accessed 21
- 508 September 2023.
- 509 17. Australian Government Department of Health and Aged Care. TGA provisionally
- 510 approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY).
- 511 https://www.tga.gov.au/news/media-releases/tga-provisionally-approves-
- 512 glaxosmithklines-covid-19-treatment-sotrovimab-xevudy. Accessed 21 September
- 513 2023.
- 514 18. Medicines & Healthcare products Regulatory Agency. Summary of product
- 515 characteristics for Xevudy. https://www.gov.uk/government/publications/regulatory-
- 516 approval-of-xevudy-sotrovimab/summary-of-product-characteristics-for-xevudy.
- 517 Accessed 21 September 2023.
- 518 19. GSK. Xevudy (sotrovimab) granted marketing authorisation by the European

519 Commission for the early treatment of COVID-19. https://www.gsk.com/en-

- 520 gb/media/press-releases/xevudy-sotrovimab-granted-marketing-authorisation-by-the-
- 521 european-commission-for-the-early-treatment-of-covid-19/. Accessed 21 September522 2023.
- 523 20. GSK. GSK received approval for monoclonal antibody, "XEVUDY for intravenous 524 injection" (generic name: sotrovimab), for the treatment of COVID-19.

It is made available under a CC-BY 4.0 International license .

525 https://jp.gsk.com/media/7512/20210927_	_xevudy-approval-e.pdf. Accessed 21
---	-------------------------------------

- 526 September 2023.
- 527 21. Mendiola-Pastrana IR, López-Ortiz E, Río de la Loza-Zamora JG, González J,
- 528 Gómez-García A, López-Ortiz G. SARS-CoV-2 variants and clinical outcomes: a
- 529 systematic review. Life (Basel). 2022;12:170.
- 530 22. World Health Organization. Coronavirus disease (COVID-19) pandemic.
- 531 https://www.who.int/europe/emergencies/situations/covid-19. Accessed 21
- 532 September 2023.
- 533 23. Superior Health Council. COVID-19 vaccination: autumn / winter season 2022 -
- 534 2023. SHC № 9721.
- 535https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/25360220706_shc-9721_covid-19_booster_automn-winter_2022-2023_vweb.pdf.
- 537 Accessed 21 September 2023.
- 538 24. Park YJ, Pinto D, Walls AC, Liu Z, De Marco A, Benigni F, et al. Imprinted antibody
- 539 responses against SARS-CoV-2 Omicron sublineages. Science. 2022;378:619-27.
- 540 25. Jonckheer P, Jespers V, Costa E, Castanares-Zapatero D, Roberfroid D, Hulstaert F.
- 541 Task Force COVID Therapeutics. Home-based medication management for non-
- 542 severe SARS-CoV-2 infection. https://kce.fgov.be/sites/default/files/2022-
- 543 05/COVID19_Therapeutics_for_GPs_NoteKCE_06052022.pdf. Accessed 21
- 544 September 2023.
- 545 26. Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Whitener B, et al. Resilience of
 546 S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV547 2 Omicron lineage strains. Nat Commun. 2022;13:3824.

548 27. Uraki R, Kiso M, lida S, Imai M, Takashita E, Kuroda M, et al. Characterization and 549 antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;607:119-27. 550 28. Sciensano. Belgium COVID-19 epidemiological situation: variants. 551 https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-552 0369173148ab/page/urrUC. Accessed 21 September 2023. 553 29. Sciensano. Belgium COVID-19 epidemiological situation: hospitalisations - clinical 554 surveillance. https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-555 848c-0369173148ab/page/JL1qB. Accessed 21 September 2023. 556 30. Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A, et al. Real-557 world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during 558 Omicron BA.2 subvariant predominance: a systematic literature review. medRxiv. 559 2023;doi.org/10.1101/2023.03.09.23287034. 560 31. Sciensano. Belgium COVID-19 epidemiological situation: deaths. 561 https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-562 0369173148ab/page/QTSKB. Accessed 21 September 2023. 563 32. Wang C, Liu B, Zhang S, Huang N, Zhao T, Lu QB, et al. Differences in incidence 564 and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in 565 relation to vaccine coverage: a world-wide review. J Med Virol. 2023;95:e28118. 566 33. Sigal A, Milo R, Jassat W. Estimating disease severity of Omicron and Delta SARS-567 CoV-2 infections. Nat Rev Immunol. 2022;22:267-9. 568 34. Cheng MM, Reves C, Satram S, Birch H, Gibbons DC, Drysdale M, et al. Real-world 569 effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2

570 Delta and Omicron waves in the USA. Infect Dis Ther. 2023;12:607-21.

It is made available under a CC-BY 4.0 International license .

571	35.	Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, et al. Comparative
572		effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19
573		outcomes in patients in the community: observational cohort study with the
574		OpenSAFELY platform. BMJ. 2022;379:e071932.

575 36. Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J, et al.
576 Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases
577 treated with sotrovimab in the community in England. Influenza Other Respir Viruses.

578 2023;17:e13150.

- 37. Razonable RR, Tulledge-Scheitel SM, Hanson SN, Arndt RF, Speicher LL, Seville
 TA, et al. Real-world clinical outcomes of bebtelovimab and sotrovimab treatment of
 high-risk persons with coronavirus disease 2019 during the Omicron epoch. Open
 Forum Infect Dis. 2022;9:ofac411.
- 583 38. Evans A, Qi C, Adebayo JO, Underwood J, Coulson J, Bailey R, et al. Real-world
 584 effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing
 585 hospital admission among higher-risk patients with COVID-19 in Wales: a

586 retrospective cohort study. J Infect. 2023;86:352-60.

587 39. Patel V, Yarwood MJ, Levick B, Gibbons DC, Drysdale M, Kerr W, et al.

588 Characteristics and outcomes of patients with COVID-19 at high-risk of disease

589 progression receiving sotrovimab, oral antivirals or no treatment in England.

590 medRxiv. 2022;doi.org/10.1101/2022.11.28.22282808.

- 40. Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, et
- al. Experience with sotrovimab treatment of SARS-CoV-2-infected patients in
- 593 Denmark. Br J Clin Pharmacol. 2023;89:1820-33.
- 41. De Mot L, Robalo Q, Dockx Y, Vandromme M, De Pauw R, Serrien B, et al. COVID-
- 595 19 clinical hospital surveillance report. https://covid-


It is made available under a CC-BY 4.0 International license .

- 596 19.sciensano.be/sites/default/files/Covid19/COVID-
- 597 19_Hospital_epidemiology_Part_1.pdf. Accessed 21 September 2023.
- 598 42. Sciensano. Belgium COVID-19 epidemiological situation: vaccination.
- 599 https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-
- 600 0369173148ab/page/p_j1f02pfnpc. Accessed 21 September 2023.
- 601

602 Additional files

- Additional file 1 (PDF) Supplementary Appendix, containing ATC and ICD-10 codes used in
- 604 this study, and all-cause and COVID-19-related outcomes by study month

It is made available under a CC-BY 4.0 International license .



acute respiratory syndrome coronavirus 2